发明授权
US08586599B2 Polymorphic forms of 6-(1-methyl-1H-pyrazol-4-yl)-2-{3-[5-(2-morpholin-4-yl-ethoxy)-pyrimidin-2-yl]-benzyl}-2H-pyridazin-3-one dihydrogenphosphate and processes of manufacturing thereof
有权
6-（1-甲基-1H-吡唑-4-基）-2- {3- [5-（2-吗啉-4-基 - 乙氧基） - 嘧啶-2-基] - 苄基} -2H的多晶型 哒嗪-3-酮磷酸二氢盐及其制备方法
![Polymorphic forms of 6-(1-methyl-1H-pyrazol-4-yl)-2-{3-[5-(2-morpholin-4-yl-ethoxy)-pyrimidin-2-yl]-benzyl}-2H-pyridazin-3-one dihydrogenphosphate and processes of manufacturing thereof](/docs/US/2013-11-19/US08586599B2/abs.jpg.600x600.jpg)
- 专利标题： Polymorphic forms of 6-(1-methyl-1H-pyrazol-4-yl)-2-{3-[5-(2-morpholin-4-yl-ethoxy)-pyrimidin-2-yl]-benzyl}-2H-pyridazin-3-one dihydrogenphosphate and processes of manufacturing thereof
- 专利标题（中）： 6-（1-甲基-1H-吡唑-4-基）-2- {3- [5-（2-吗啉-4-基 - 乙氧基） - 嘧啶-2-基] - 苄基} -2H的多晶型 哒嗪-3-酮磷酸二氢盐及其制备方法
-
申请号： US13141142申请日： 2009-11-24
-
公开(公告)号： US08586599B2公开(公告)日： 2013-11-19
- 发明人: Axel Becker , Clemens Kuehn , Christoph Saal , Oliver Schadt , Dieter Dorsch , Eva Kriegbaum , Frank Stieber , Cristina Donini
- 申请人： Axel Becker , Clemens Kuehn , Christoph Saal , Oliver Schadt , Dieter Dorsch , Eva Kriegbaum , Frank Stieber , Cristina Donini
- 申请人地址： DE Darmstadt
- 专利权人： Merck Patent GmbH
- 当前专利权人： Merck Patent GmbH
- 当前专利权人地址： DE Darmstadt
- 代理机构： Millen, White, Zelano & Branigan, P.C.
- 优先权： EP08022253 20081222
- 国际申请： PCT/EP2009/008358 WO 20091124
- 国际公布： WO2010/072295 WO 20100701
- 主分类号： A61K31/501
- IPC分类号： A61K31/501 ; A61K31/5377 ; C07D413/14 ; C07D403/14
![Polymorphic forms of 6-(1-methyl-1H-pyrazol-4-yl)-2-{3-[5-(2-morpholin-4-yl-ethoxy)-pyrimidin-2-yl]-benzyl}-2H-pyridazin-3-one dihydrogenphosphate and processes of manufacturing thereof](/abs-image/US/2013/11/19/US08586599B2/abs.jpg.150x150.jpg)
摘要：
The present invention relates to 6-(1-methyl-1H-pyrazol-4-yl)-2-{3-[5-(2-morpholin-4-yl-ethoxy)-pyrimidin-2-yl]-benzyl}-2H-pyridazin-3-one dihydrogenphosphate, its solvates and crystalline modifications thereof. The present invention further relates to processes of manufacturing these crystalline modifications as well as their use in the treatment and/or prophylaxis of physiological and/or pathophysiological conditions, which are caused, mediated and/or propagated by the inhibition, regulation and/or modulation of signal transduction of kinases, in particular by the inhibition of tyrosine kinases, e.g. pathophysiological conditions such as cancer.
公开/授权文献
信息查询
IPC分类:
